AU2001253727A1 - Methods for identifying compounds useful for preventing acute clinical vascular events in a subject - Google Patents

Methods for identifying compounds useful for preventing acute clinical vascular events in a subject

Info

Publication number
AU2001253727A1
AU2001253727A1 AU2001253727A AU5372701A AU2001253727A1 AU 2001253727 A1 AU2001253727 A1 AU 2001253727A1 AU 2001253727 A AU2001253727 A AU 2001253727A AU 5372701 A AU5372701 A AU 5372701A AU 2001253727 A1 AU2001253727 A1 AU 2001253727A1
Authority
AU
Australia
Prior art keywords
subject
methods
compounds useful
identifying compounds
preventing acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253727A
Inventor
Ira Tabas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of AU2001253727A1 publication Critical patent/AU2001253727A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001253727A 2000-04-21 2001-04-20 Methods for identifying compounds useful for preventing acute clinical vascular events in a subject Abandoned AU2001253727A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55392700A 2000-04-21 2000-04-21
US09/553,927 2000-04-21
PCT/US2001/012877 WO2001080715A2 (en) 2000-04-21 2001-04-20 Methods for identifying compounds useful for preventing acute clinical vascular events in a subject

Publications (1)

Publication Number Publication Date
AU2001253727A1 true AU2001253727A1 (en) 2001-11-07

Family

ID=24211352

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253727A Abandoned AU2001253727A1 (en) 2000-04-21 2001-04-20 Methods for identifying compounds useful for preventing acute clinical vascular events in a subject

Country Status (3)

Country Link
US (1) US20040259853A1 (en)
AU (1) AU2001253727A1 (en)
WO (1) WO2001080715A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011426A2 (en) 2002-07-30 2004-02-05 The Regents Of The University Of California Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
US20050202406A1 (en) 2003-11-25 2005-09-15 The Regents Of The University Of California Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems
TW200538738A (en) 2004-02-20 2005-12-01 Univ California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
WO2007024589A2 (en) * 2005-08-24 2007-03-01 The Trustees Of Columbia University In The City Of New York Phagocyte enhancement therapy for atherosclerosis
US20110152112A1 (en) * 2009-12-23 2011-06-23 Artery Therapeutics, Inc. Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
JP2014526685A (en) 2011-09-08 2014-10-06 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Metabolic flow measurement, imaging, and microscopy
ES2668678T3 (en) 2011-12-07 2018-05-21 Glaxosmithkline Llc Procedure for determining total body skeletal muscle mass
CN103275911B (en) * 2013-01-02 2015-11-25 温州医学院 A kind of intestinal bacteria containing pET-28a (+)-protein400 recombinant plasmid and preparation method thereof
US9134319B2 (en) 2013-03-15 2015-09-15 The Regents Of The University Of California Method for replacing biomarkers of protein kinetics from tissue samples by biomarkers of protein kinetics from body fluids after isotopic labeling in vivo
FR3014694B1 (en) * 2013-12-13 2016-11-11 Roquette Freres METHYL-CYCLODEXTRIN-BASED COMPOSITIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES BY INCREASING THE CHOLESTEROL-HDL RATE
CN106957819A (en) * 2016-01-11 2017-07-18 中国科学院上海生命科学研究院 A kind of method for improving T cell activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921838A (en) * 1987-06-16 1990-05-01 Trustees Of Boston University Angiogenic and blood perfusion inducing properties of amphiphilic compounds
JP2002011870A (en) * 2000-04-28 2002-01-15 Omron Corp Method for printing code and code format
US7029863B2 (en) * 2001-03-14 2006-04-18 The Children's Hospital Of Philadelphia Cell culture system for determining the cholesterol efflux potential for serum
WO2003092467A2 (en) * 2002-04-30 2003-11-13 The Trustees Of Columbia University In The City Of New York Compositions and methods relating to abca1-mediated cholesterol efflux

Also Published As

Publication number Publication date
WO2001080715A3 (en) 2004-02-26
US20040259853A1 (en) 2004-12-23
WO2001080715A2 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
AU2001283163A1 (en) Automatic transaction management
EP1277117A4 (en) Interface for presenting information
AU2002236483A1 (en) Method for utilizing oral movement and related events
AU2002230523A1 (en) Clinically intelligent diagnostic devices and methods
AU2001286360A1 (en) Method and system for identifying a user
AU2001288293A1 (en) Scannable barcode display and methods for using the same
AU2001290616A1 (en) A method for identifying polymorphisms
AU2002228639A1 (en) Collecting information before or during a call
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU2001253727A1 (en) Methods for identifying compounds useful for preventing acute clinical vascular events in a subject
AU2001243394A1 (en) Compounds and methods
HK1041346A1 (en) Case for information disks
AU2001238152A1 (en) Insecticidal compounds and methods for selection thereof
AU2002241739A1 (en) Antimycobacterial compounds and method for making the same
AU2000264672A1 (en) A disc for a disc brake
AU2002246912A1 (en) Receptor-binding compounds and methods for identifying them
AU2001278951A1 (en) Compounds and methods
AU2002216017A1 (en) Case for a blood bag and method for producing the same
AU5502599A (en) A footware for health
AU2001265071A1 (en) Clinical trial management
AU2002218457A1 (en) Methods for identifying pesticidal compounds
AU2000259734A1 (en) Method for identifying compounds with anti-herpes activity
AUPR022000A0 (en) Automated wagering
AU2002222351A1 (en) Managing a medical procedure